Skip to content
value.today
CEL Sci Corp. logo

CEL Sci Corp.

CEL Sci Corp. is listed today as CEL-SCI Corporation: market value, financials and filings are on its company page.

Funding rounds

0 counted as startup funding, 1 other private sales on record. Open the number of investors for the round's details.

Funding rounds of CEL Sci Corp.
MonthRaisedRaiseSizeInvestorsSoldFiling
Feb 2017$1 MPrivate placement after listingUnder $2 million

CEL Sci Corp.: Private sale, Feb 2017

Investors in this round

2 investors had bought by the notice of Feb 28, 2017: 2 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$1 M of $1 M offered
Smallest investment taken
$1,000
What was sold
options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Up to $1 million
Sales commissions
$70,000
Finders' fees
none
Paid to its own people
$142,000 (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks payments to its own people as estimates
The company
Corporation, incorporated in Colorado

People named in the notice

  • Daniel H. Zimmerman · Executive Officer
  • Eyal B. Talor · Executive Officer
  • Geert R. Kersten · Executive Officer, Director
  • John H. Cipriano · Executive Officer
  • Patricia B. Prichep · Executive Officer
  • Alexander G. Esterhazy · Director
  • Bruno R. Baillavoine · Director
  • Peter R. Young · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • H.C. Wainwright & Co., LLC · New York, New YorkSold in all US states

Signed by Geert R. Kersten, Chief Executive Officer. Source: SEC Form D, newest notice filed Feb 28, 2017. Read the notice at the SEC.

optionsSEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • CEL Sci Corp. had revenue of up to $1 million when it filed its newest notice of a funding round (Feb 2017).

    SEC Form D (revenue range) · Feb 2017

  • The industry group it chose in its notices: Pharmaceuticals.

    SEC Form D · Feb 2017

Products and services#

No products or services of CEL Sci Corp. are on record.

Investors#

No investor of CEL Sci Corp. is named in an official source we use. Its funding notices give only how many investors bought, not who they are.

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete.

Largest shareholders today

Institutions holding CEL-SCI Corporation shares, as of Sep 30, 2026.

Source: SEC Form 13F holdings reports · as of Sep 30, 2026. Value held and share of the company. All holders are on the company page.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by CEL Sci Corp.
NameRoleNamed in
Daniel H. ZimmermanExecutive officerFeb 2017
Eyal B. TalorExecutive officerFeb 2017
Geert R. KerstenExecutive officerFeb 2017
John H. CiprianoExecutive officerFeb 2017
Patricia B. PrichepExecutive officerFeb 2017
Alexander G. EsterhazyDirectorFeb 2017
Bruno R. BaillavoineDirectorFeb 2017
Geert R. KerstenDirectorFeb 2017
Peter R. YoungDirectorFeb 2017

About

American biotechnology company.

Went public since 1997. Its SEC number is that of a company listed on a stock exchange.